Constitutive RAS activation in NRAS-mutant CMs, and alternative splicing of BRAF V600E in the absence of RAS activity, promote RAF dimerization, which drives tumor progression and resistance to BRAFi (Brummer & McInnes, 2020). The gene discussed is BRAF; the disease is neoplasm.